Opinion: What It Means When Motherhood Means Peeing Yourself in Public
I'm watching my 8-year-old son try to con a nurse out of $500 by selling her a hunk of plastic he's labeled a 'blood diamond' when a mom next to me in the hospital waiting room leans over to ask: 'Is it the disease, you think?'
She's referring to adrenoleukodystrophy, the terrifying brain-devouring disease that her son shares with mine. 'Behavioral changes' are one of the tell-tale signs of its progression.
At this moment, though, I can safely say, 'No, my son's always been this way.'
Just moments earlier, a nurse who'd drawn his blood gave him a plastic coin with which to get himself a prize from a nearby toy machine. He pocketed the piece of plastic jewelry he'd won but returned to her looking downtrodden, whining, 'The machine ate my coin and didn't give me anything!'
'He's trying to scam you, don't fall for it!' I shouted from across the hall, my son unleashing a devilish grin as the nurse chuckled. The coin scam quickly turned into the 'blood diamond' scam with the gemstone he'd acquired and the other unsuspecting nurse further down the hall.
'Well he definitely seems to be doing better!' she says.
The last time this particular nurse had seen him, he'd asked to be euthanized. He was in the throes of chemo-induced agony, when no variation of 'this will be worth it in the end' could convince him that being brought to the brink of death really was his best chance at survival.
In less than three months, I've seen looks in his eyes that I'll never shake. I've watched him throw up blood. I've scrubbed up his puke and diarrhea with industrial-grade antiseptics so many times my hands have peeled and bled. I've sat through the night at his bedside and watched his chest rise and fall, so afraid that it might stop.
Countless other moms of sick children have gone through exactly the same thing. It sounds dramatic, but it requires little to no thinking—it's second nature, maybe even first. We call it motherhood, but I prefer to think it's one of those things that's too innate to have a name. Americans will celebrate that very unprofound national holiday in honor of this very profound thing this weekend, around the time my son and I find out if he has or has not been granted a reprieve from his childhood death sentence.
It will have special meaning for me.
In my case, it means watching my son turn around and smile at me and suddenly seeming, for one fleeting moment, to be cured of his deadly brain disease. And maybe he is. I feel a flush of warmth at the thought.
But then my legs give out and I crumple to the concrete floor like soggy cardboard and my son's expression changes as we both understand how much my own degenerative disease has progressed while his was being treated.
That is what it means to be a mother. Dying in slow motion to save your child.
I was told initially I could probably avoid ending up in a wheelchair. Diagnosed two years before my son's much scarier disease was detected, my autoimmune disease, multiple sclerosis, at first seemed like the biggest struggle our family would have to face.
'Avoid stress,' my neurologist had told me. 'Stress is the one thing we know will speed up progression. Get good sleep, eat healthy, exercise as much as you can and make whatever lifestyle changes you need to in order to minimize stress.'
I did as I was told, but a stress-free life wasn't in the cards. All that mattered in terms of my own illness when my son got sick was staving off progression long enough to ensure I could still be on my feet to tend to him as he underwent his bone marrow transplant.
'Just get him through it,' I told myself. 'We can't both be bedridden at the same time.'
I'm still not sure if it's funny or tragic that my son and I both wound up with degenerative diseases. I prefer to think my son's case is tragic, while mine is darkly humorous.
Like the time we were stuck in traffic, rushing to get him to a doctor's appointment for a test that would tell us if he was dying or not. It was the perfect time for the bladder issues caused by the lesions in my spine to remind me why I should never be too far from a toilet.
I peed myself in the car.
'It's me, not him. He's fine,' I responded brusquely to the looks of concern and queries about the stench of urine when we finally got to the hospital. (Loss of bladder control also happens to be a worrying milestone in my son's disease.)
As President Donald Trump flirts with the idea of 'baby bonuses' to boost the birth rate, I wonder if he's ever seen this side of parenting. If he's ever wet himself to put his child first. But of course that would be too much of a downer for his $5,000 gimmick and the White House lie that he 'wants America to be a country where all children can safely grow up and achieve the American dream.'
Not all children, let's be honest. Not the ones with cruel diseases that are too rare to matter to his administration. But mothers don't need a $5,000 cash incentive to fight for their kids. I'd gladly spend another 100 days scrubbing up my son's bile and holding his hand when he hurts, even as I stifle my own cries of pain. I'd do it all again, and then a thousand times more, and I'd do it until I died and then keep doing it from beyond the grave if it meant saving him.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Forbes
17 minutes ago
- Forbes
Firing Of Vaccine And Cancer Advice Panels Raises Question, What Next?
WASHINGTON, DC: Secretary of Health and Human Services Robert F. Kennedy Jr. testifies before the ... More Senate Committee on Health, Education, Labor, and Pensions on Capitol Hill on May 20, 2025. Kennedy testified Department of HHS's proposed 2026 fiscal year budget.(Photo by) Earlier this year, the National Institutes of Health dismantled the National Cancer Institute's Board of Scientific Advisors, which had 28 members. And now Health and Human Services Secretary Robert F. Kennedy Jr fired the entire 17-member Advisory Committee on Immunization Practices that provides recommendations on vaccines to the Centers for Disease Control and Prevention. This raises the question, who's going to do the advising? With no replacement forthcoming, at NCI it would appear that the National Cancer Advisory Board will have to go it alone. At ACIP, it's likely Kennedy will appoint people to the advisory committee without a vaccine industry pedigree, including like-minded vaccine skeptics. The importance of having independent expert panels in the oncology and vaccine spaces is hard to overstate. Cancer is America's second-leading cause of death. NCI is the nation's premier funder of cancer research. And regarding vaccines, from smallpox inoculations—which began in the late 18th century and ended when the disease was eradicated in the 1970s—to mumps, rubella, tetanus, diphtheria, polio, measles, hepatitis B, human papilloma virus, respiratory syncytial virus, pneumococcal and COVID-19 immunizations, vaccinations have saved millions of lives and prevented life-threatening illnesses from occurring. What happens next in terms of decisions by Kennedy and the various HHS agencies will matter considerably to public health. Kennedy seeks to radically reshape the vaccine policy landscape as he ousts CDC's ACIP, which advises the CDC director on which vaccines approved by the Food and Drug Administration should be used; for example, recommending which groups of people ought to be vaccinated, at what doses and when. For decades, ACIP's guidance has been based on an independent, non-politicized review of the peer-reviewed scientific research as well as debate among the committee experts. ACIP's guidance is not binding, though CDC almost always follows it and provides recommendations to the public on what is to be included in the United States adult and childhood immunization schedules. In a press release issued by the Department of HHS on June 9th, Kennedy says he's doing this in order to restore the public's trust in vaccine science in America. It's unknown who Kennedy will hire to replace committee members, but it's possible that at least some of the people he appoints will share his skeptical views of vaccines. The Department of HHS said ACIP will still meet June 25-27, but with new membership. This means that between now and then, presumably we'll know the list of new members. In determining who's to be on the ACIP committee, Kennedy says he wants to eliminate conflicts of interest that panel members may have with the industry. But Science describes an already existing process in place for vetting candidates and probing for potential conflicts of interest. Indeed, looking at the current ACIP members, conflicts of interest aren't readily apparent among the large number of academics, a chief medical officer of a community health center, a state public health official and the owner of a family medicine practice. But Kennedy seems to view them differently. Given that several members have prior to their ACIP membership pursued research funded in part by grants to universities from the pharmaceutical industry, while others have advocated for certain childhood vaccinations, in Kennedy's eyes they're probably seen as part of the vaccine establishment. The NIH dismissed all 28 members of the Board of Scientific Advisors to the National Cancer Institute in late April. This board had been reviewing NCI-funded extramural research and education projects for nearly three decades, often doing its work in conjunction with the National Cancer Advisory Board. In making the termination decision, the NIH director Jay Bhattacharya cited a presidential executive order calling for the culling of 'unnecessary' federal committees. This order also included an edict that the HHS Secretary end the Advisory Committee on Long COVID and that the Administrator of the Centers for Medicare and Medicaid Services discontinue the Health Equity Advisory Committee The NCI's Board of Scientific Advisors was made up of leading cancer scientists, mostly from academia, across a wide range of disease specialties. Board members did their work as a panel voluntarily, offering a deep level of expertise to the NCI, specifically around setting research priorities and giving the broader scientific community input into the NCI's extramural programs. Whether the still-existing National Cancer Advisory Board can pick up the slack and be as independent are unclear. The NIH didn't just get rid of the NCI's Board of Advisors. The NCI has also begun to face large numbers of staff terminations and closures of programs. As STAT News reported, NIH fired virtually the entire NCI communications team and a substantial number of employees in the Office of Advocacy Relations. The NCI Outstanding Investigator award program was also canceled. More cuts are expected, as the NCI has been ordered to 'significantly' reduce its contracts budget. This budget can cover, among other things, support for clinical trials, certain lab scientists, a cancer registry to collect, store and manage data on persons with cancer, scientific databases and a repair service for critical lab equipment. On top of this, the New York Times is tallying the full extent of the cuts in research grant funding across all parts of the NIH, including the NCI. Currently, at least 2,500 grants have been canceled or delayed, impacting many therapeutic areas such as cancer, but also vaccine development and research on how to improve vaccination outreach.
Yahoo
19 minutes ago
- Yahoo
PlushCare Launches Enhanced Online Weight Loss Program to Expand National Access to GLP-1 Prescriptions Through Board-Certified Doctors
Secure Online Access to GLP-1 Weight Loss Medications Like Semaglutide Now Available Nationwide Through PlushCare's Updated Virtual Health Platform San Francisco, June 10, 2025 (GLOBE NEWSWIRE) -- PlushCare, a leading virtual healthcare platform, has announced a significant upgrade to its online Weight Loss Program, enabling greater access to GLP-1-based prescription treatments such as semaglutide through board-certified physicians. This development marks a critical milestone in the company's mission to provide affordable, clinically supervised weight management across the United States. Accessible at the updated platform streamlines the process for eligible adults to consult with licensed physicians, receive lab work if necessary, and access customized treatment plans—all from the comfort of their homes. 'We're committed to making evidence-based weight loss solutions more accessible through modern telehealth,' said a PlushCare spokesperson. 'Our program is designed to connect people with experienced doctors who can evaluate eligibility for medications like GLP-1s and deliver a personalized plan that fits their health goals.' Expanded Features for 2025 The revamped Weight Loss Program now includes: Nationwide Access to medical providers via secure telehealth appointments Eligibility Evaluation for FDA-approved medications, including semaglutide Personalized Plans tailored to each user's metabolic profile Optional Lab Testing with integrated results for precision treatment Transparent Pricing with no insurance required The platform is optimized for mobile and desktop users, offering a seamless experience from appointment scheduling to prescription delivery. Addressing a Growing National Health Concern According to the CDC, over 40% of U.S. adults struggle with obesity, with rising demand for effective clinical support. PlushCare's integrated virtual care model delivers a scalable solution that removes traditional geographic and scheduling barriers. Patients can typically get started in under 15 minutes by completing an intake form and booking a same-day appointment with a licensed doctor. If clinically appropriate, a prescription is sent to their preferred pharmacy. About PlushCare PlushCare is a virtual primary care and mental health platform that connects patients with top U.S. medical professionals through its secure telehealth platform. With a commitment to quality care, convenience, and evidence-based treatment, PlushCare is redefining access to modern healthcare. For more information, visit Media Contact:PlushCare Media RelationsEmail: press@ 345 California Street, Suite 600, San Francisco, CA 94105, United States SOURCE: PlushCare Disclaimer: This release contains forward-looking statements and should not be considered medical advice. All treatments are subject to clinical evaluation and provider discretion. CONTACT: Email: press@ in to access your portfolio


TechCrunch
30 minutes ago
- TechCrunch
Vijay Pande, founding partner of a16z bio and health strategy, steps down
In Brief Vijay Pande, a general partner at Andreessen Horowitz who founded the firm's a16z Bio+ Health strategy, announced that he is stepping down from his role. Since its founding in 2014, a16z Bio+ Health has raised four funds of nearly $3 billion each, including a $1.5 billion fund that closed in 2022. However, it's now seeking a much smaller $750 million fifth fund, The Wall Street Journal reported. In January, a16z Bio+ Health announced that it will manage a $500 million biotech fund funded by pharmaceutical giant Eli Lilly. a16z Bio + Health backs digital health startups and companies at the intersection of AI, computation, and biology. Pande's investments include Devoted Health, an individualized medical plan provider; Function Health, a personalized lab testing startup; and Freenome, a company aiming to detect cancer through blood draws. Before joining Andreessen Horowitz, Pande was a professor of chemistry, structural biology, and computer science at Stanford University. The remaining partners on the a16z Bio + Health team are Jorge Conde, Julie Yoo, and Vineeta Agarwala.